Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan Deeping Debate on LLP Copay Review; Focus Is on Exclusion Criteria, Payment Levels, G1/G2 Rule Change
Japan’s all-important reimbursement policy panel has started detailed discussions on the proposed copay review of off-patent brand-name drugs, called long-listed products (LLPs), which would require additional out-of-pocket payments for patients who use these medicines. The plan is to require patients…
To read the full story
Related Article
- MHLW Clarifies Criteria for “Medical Necessity” of LLPs before Elective Care Rollout
July 17, 2024
- Japan Unveils 1,095 Off-Patent Branded Drugs Subject to New Coverage Rule
April 23, 2024
- MHLW Defines “Long-Listed Products” towards Rollout of New Coverage Rule
April 1, 2024
- Chuikyo to Discuss Exclusion of Long-Listed Biologics from New Coverage Scheme
January 29, 2024
- Chuikyo Officially OKs Application of Elective Care for Off-Patent Branded Drugs
December 28, 2023
- Japan to Roll Out New LLP Coverage Rule in October; 18 Billion Yen Saving Eyed for FY2024
December 21, 2023
- Chuikyo Split on Copay Rate under Elective Care Scheme; Political Decision Likely over 1/2 or 1/4
December 18, 2023
- Japan Panel OKs Basic Plan for Elective Care Scheme for LLPs; 900 APIs Targeted
December 11, 2023
- Proposed Introduction of Elective Care Scheme for LLP Copay “Hard to Understand”: Chuikyo Members
December 4, 2023
- Panelists Urge Exclusion of LLPs from Copay Increase If Generic Access Is Difficult
November 30, 2023
- Japan Panel Supports Certain Out-of-Pocket Payment for LLP-Generic Price Gap
November 10, 2023
- As Copay Debate Picks Up Steam, MHLW Floats 4 Ideas for Coverage Reform
October 2, 2023
- With Generics Now in Common Use, It’s Time for Debate on LLP Copay: Payers
August 4, 2023
REGULATORY
- Japan Eyes Multi-Year Funding to Secure MCMs: Takaichi
October 14, 2026
- Pharma Continues Reform Push at 2nd Public-Private Subgroup Meeting
October 13, 2026
- AbbVie’s TrenibotE Up for Review on Oct. 26, Aquipta on Agenda Too
October 13, 2026
- Japan Panel to Review Full Approval of Nipro’s Stemirac on October 15
October 13, 2026
- Japan Finalizes Medical Data Sharing Blueprint, Eyes 2027 Bill
October 13, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…